Variant adeno-associated viruses and methods of using
Joshua Dudman, Leesburg, VA (US); Adam Hantman, Ashburn, VA (US); Bum-Yeol Hwang, Moraga, CA (US); Alla Karpova, Ashburn, VA (US); Loren Looger, Sterling, VA (US); Kimberly Ritola, Ashburn, VA (US); David Schaffer, Danville, CA (US); Dougal Gowanlock Robinson Tervo, Ashburn, VA (US); and Sarada Viswanathan, Ashburn, VA (US)
Assigned to Howard Hughes Medical Institute, Chevy Chase, MD (US)
Filed by Howard Hughes Medical Institute, Chevy Chase, MD (US); and The Regents of the University of California, Oakland, CA (US)
Filed on Mar. 23, 2021, as Appl. No. 17/209,336.
Application 17/209,336 is a continuation of application No. 16/310,332, granted, now 10,961,282, previously published as PCT/US2017/037781, filed on Jun. 15, 2017.
Claims priority of provisional application 62/404,585, filed on Oct. 5, 2016.
Claims priority of provisional application 62/350,361, filed on Jun. 15, 2016.
Prior Publication US 2021/0230231 A1, Jul. 29, 2021
1. An adeno-associated virus 2 (AAV2) VP1 capsid protein comprising an amino acid sequence comprising SEQ ID NOs:82, 85, or 86 inserted between amino acids N587 and R588 of the AAV2 VP1 capsid protein, numbered relative to SEQ ID NO:110.